New drug combo aims to boost head and neck cancer treatment
NCT ID NCT06110195
First seen Apr 03, 2026 · Last updated May 07, 2026 · Updated 5 times
Summary
This study tested a new drug called xevinapant combined with chemotherapy and radiation for people with head and neck cancer who cannot take the standard drug cisplatin. The goal was to find the safest dose and see how well the combination works. The study was stopped early, but the results may help design future trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.